Email Updates

You are here

AVAC in the News

  • Just before Christmas, the US Food and Drug Administration (FDA) announced that it had approved an injectable formulation of the HIV drug cabotegravir for use as PrEP. The drug, to be given as an injection every two months, will be branded as Apretude in the US. Although FDA approval came earlier than expected, they could have hardly rejected it.

    January 7, 2022
    aidsmap
  • Financial support for the research and development (R&D) of HIV prevention declined in 2020, marking a drop for the second year in a row and continuing an eight-year trend of either decreased or flat funding, according to the latest annual report on the topic from AVAC, a global organization focused on HIV prevention.

    December 28, 2021
    POZ
  • The first long-acting injectable for HIV prevention has now been approved for use, the FDA announced on Monday. Long-acting injectable cabotegravir (CAB-LA, branded as Apretude) is administered as a monthly injection for the first 2 months, then every 2 months afterwards. It is the first long-acting injectable for pre-exposure prophylaxis (PrEP). The drug is approved for adults and adolescents weighing at least 77 lb.

    December 22, 2021
    MedPage Today
  • There had been more 200,000 pre-exposure prophylaxis (PrEP) initiations in North America from 2016-2020, according to data from the AVAC earlier this year. While the US is highly contributory to the gradually increasing rate of HIV-risk persons gaining access to PrEP annually, it’s not enough to consider the work accomplished on a national scale.

    December 22, 2021
    Contagion Live
  • There had been more 200,000 pre-exposure prophylaxis (PrEP) initiations in North America from 2016-2020, according to data from AVAC earlier this year. While the US is highly contributory to the gradually increasing rate of HIV-risk persons gaining access to PrEP annually, it’s not enough to consider the work accomplished on a national scale.

    December 15, 2021
    HCP Live
  • In the US, women account for a fifth of new infections. But a persistent lack of education means few even know about the highly effective medication known as PrEP.

    December 1, 2021
    National Geographic
  • Every Dec. 1, the world commemorates those who have died from an AIDS-related illness. Known as World AIDS Day, it serves as a reminder that there has been an ongoing pandemic for the past 40 years, pre-dating COVID. The COVID vaccines were sequenced, developed and approved in the US in record time, but that would not have been possible without decades of work by HIV researchers.

    December 1, 2021
    CNBC
  • The COVID-19 pandemic has complicated — and in some cases halted — the fight against HIV/AIDS. We talk about that impact with Hombisa Ntsikanye, an implementer and developer of the HIV and AIDS program at Blue Roof Life Space in Durban, South Africa; and Mitchell Warren, executive director of the AIDS Vaccine Advocacy Coalition.

    December 1, 2021
    General
    CBC
  • Dr. Anthony Fauci, the top US infectious disease expert, said Tuesday the COVID-19 pandemic has diverted scientific and financial resources from the fight against AIDS, seriously impeding global efforts to achieve the UN goal of ending AIDS by 2030.

    December 1, 2021
    NBC News
  • There have been several shifts in the UNAIDS ethics guidance with implications for HIV vaccine researchers submitting applications for initial ethics review or re-certification, and for RECs conducting such reviews. This review may assist RECs in a more efficient and consistent application of ethics recommendations. However, additional tools and training may further help stakeholders comply with new UNAIDS ethics recommendations during protocol development and ethics review.

    November 21, 2021
    JIAS

Pages